European Society of Cardiology (ESC) Congress 2025 Late Breaking Results Confirm Caristo FAI-Score™ Technology's Superior and Complementary Predictive Value for Cardiac Death Beyond hsCRP

Study results confirmed FAI-Score's predictive value for cardiac mortality: Study results confirmedFAI-Score 's predictive value for cardiac mortality: Caristo'sFAI-Scoretechnology was originally developed atOxford Universitywith funding from The British Heart Foundation ( BHF ). ProfessorCharalambos Antoniades, BHF Chair of Cardiovascular Medicine at theUniversity of Oxford and lead investigator of the study, commented: "Inflammation is a key process for coronary...

Study results confirmed FAI-Score's predictive value for cardiac mortality:

Caristo's FAI-Score technology was originally developed at Oxford University with funding from The British Heart Foundation (BHF).

Professor Charalambos Antoniades, BHF Chair of Cardiovascular Medicine at the University of Oxford and lead investigator of the study, commented: "Inflammation is a key process for coronary atherosclerosis, and FAI-Score is known to predict inflammatory risk. Interestingly, our study unveils the specific inflammatory pathways within the human arteries that are captured by FAI-Score, and confirms its specificity for local inflammatory pathways within the human arteries different to what is captured by hsCRP. This opens up new opportunities for using the CaRi-HeartFAI-Score technology to guide treatments in clinical practice."

Caristo Diagnostics is on a mission to transform the diagnosis and treatment of cardiovascular disease, and its CaRi-Heart technology is the only product around the world with the FAI-Score capabilities. CaRi-Heart technology is regulatory cleared for use in Europe, UK, Australia, and is pending FDA clearance for U.S. clinical use. In the meantime, the company has achieved two significant U.S. regulatory milestones in 2025. The AMA CPT Panel approved a new Category III CPT® for the CaRi-Heart technology. In addition, the Food and Drug Administration (FDA) granted clearance for Caristo's CaRi-Plaque™ technology for plaque and stenosis quantification.

About Caristo Diagnostics
Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com. Find Caristo online on LinkedIn, YouTube, and X.

Logo - https://mma.prnewswire.com/media/2054669/5504742/Caristo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/european-society-of-cardiology-esc-congress-2025-late-breaking-results-confirm-caristo-fai-score-technologys-superior-and-complementary-predictive-value-for-cardiac-death-beyond-hscrp-302553724.html